US 12,303,534 B2
Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
Yun Sun Yang, Seongnam-si (KR); Wonil Oh, Seongnam-si (KR); Soo Jin Choi, Seongnam-si (KR); Jihye Kwak, Seongnam-si (KR); Dong Hyon Kim, Seongnam-si (KR); and Hoon Lim, Seongnam-si (KR)
Assigned to MEDIPOST CO., LTD, Seongnam-si (KR)
Appl. No. 16/972,118
Filed by MEDIPOST CO., LTD., Seongnam-si (KR)
PCT Filed Jun. 5, 2019, PCT No. PCT/KR2019/006817
§ 371(c)(1), (2) Date Dec. 4, 2020,
PCT Pub. No. WO2019/235854, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/680,748, filed on Jun. 5, 2018.
Prior Publication US 2021/0228636 A1, Jul. 29, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61K 31/728 (2006.01); A61K 35/51 (2015.01); A61P 11/06 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01)
CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61K 31/728 (2013.01); A61K 35/51 (2013.01); A61P 11/06 (2018.01); A61P 19/02 (2018.01); A61P 25/28 (2018.01)] 8 Claims
 
1. A method for treating an inflammatory disease in a subject in need thereof, comprising,
analyzing the presence of a cell surface antigen on the surface of a population of mesenchymal stem cells, said cell surface antigen comprising HLA-A2;
determining whether 70% or more mesenchymal stem cells of the population express HLA-A2 on a surface thereof to select a population of mesenchymal stem cells of which 70% or more mesenchymal stem cells express HLA-A2; and
administering to the subject a pharmaceutical composition comprising the selected population of mesenchymal stem cells of which 70% or more mesenchymal stem cells expressing HLA-A2, thereby treating said inflammatory disease,
wherein the administration of mesenchymal stem cells increases the expression of CD163 and Arg-1 in the subject, compared to a control subject to which a physiological saline without the mesenchymal stem cells is administered,
wherein the mesenchymal stem cells are derived from umbilical cord blood, and
wherein the 70% or more mesenchymal stem cells of the population express, on the surface thereof, each of CD73, CD90, CD105, and CD166.